For years, the exhaustion of CD8+ T-cells has been the Achilles' heel of immunotherapy. We get the cells to the tumor, but they just… give up. As of March 5, 2026, researchers at the Salk Institute and UNC have identified two specific transcription factors, ZSCAN20 and JDP2, that act as the master kill-switches for cellular fatigue.
By disabling these genes, scientists have successfully rebooted exhausted T-cells, allowing them to resume their tumor-killing functions while maintaining long-term immune memory. This isn't just a marginal gain; it’s a fundamental shift in how we engineer living medicines.
